USFDA completes inspection at SMS Pharmaceuticals’ API manufacturing facility at Visakhapatnam

13 Dec 2025 Evaluate

US Food and Drug Administration (USFDA) has successfully completed inspection at SMS Pharmaceuticals’ Active Pharmaceutical Ingredient (API) manufacturing facility situated at Visakhapatnam, Andhra Pradesh. The inspection, conducted from December 08, 2025 to December 12, 2025, concluded with one minor observation in Form 483. The observation is procedural in nature and does not relate to data integrity.

The company will provide the necessary response to USFDA within the stipulated time period. The Vizag facility is a 3,000 KL flagship, multipurpose API manufacturing facility, specialising in niche, large-volume molecules. It is backed by multiple global regulatory approvals, including USFDA, WHOGMP, EU-GMP, KFDA, CDSCO, and PMDA. 

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers.


SMS Pharmaceuticals Share Price

324.05 3.30 (1.03%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×